Navigation Links
IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S.
Date:5/11/2010

the U.S. market. We plan to launch OCL 500 with a commercialization partner in the latter half of this year."

About IMBio

IMBio is a privately held Canadian biotechnology company focused on developing medical device products for use in the area of embolotherapy. Lead product, OCL 500 microspheres for the treatment of unresectable/inoperable hypervascularized tumours has received marketing clearance from the FDA in the U.S. Other products in development include rapidly-dissolving, drug-eluting and/or radio-labelled microspheres as well as biodegradable coils and stents for use in aneurysms that are not conducive to treatment with microspheres.

About Embolotherapy

Embolotherapy works by cutting off blood flow to benign and malignant hypervascular tumours. The procedure is performed by injecting agents through a catheter into the blood vessels that feed the target tumour. By selectively blocking blood supply, the deprived tumour is either destroyed or devitalized, resulting in therapeutic benefit. Hypervascular tumours are characterized by having an excessive number of blood vessels. Embolotherapy is a minimally invasive treatment for hypervascular tumours such as liver and kidney cancers as well as uterine fibroids. According to the National Cancer Institute, there are approximately 25,000 Americans with liver and intrahepatic bile duct cancer, and approximately 266,000 with kidney and renal pelvic cancer. Across the U.S., approximately 300,000 hysterectomies and 70,000 myomectomies are performed annually to treat uterine fibroids.

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the
'/>"/>

SOURCE IMBiotechnologies Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
2. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
3. Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee
4. LS9's UltraClean Diesel™ Receives EPA Registration
5. Drug Safety Firm BioSoteria Receives 2009 Best of Business Award
6. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
7. Indiana Collaborative Receives $10.3 Million in Federal Stimulus Funds to Improve Healthcare through Information Technology
8. Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications
9. MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities
10. Gems Sensors & Controls Receives ISO-13485:2003 Certification
11. BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Cell Culture Market 2014-2018" report ... Cell culture is the in vitro ... such as research, cell studies, and biopharmaceutical production. Cell ... vaccine production. Cell culture instruments and cell culture consumables ...
(Date:7/24/2014)... Your cell phone may stay charged ... storage capacity. , New research indicates that lithium-ion ... at Lawrence Livermore National Laboratory and ... components will perform as electrodes. , The growing ... for higher-performance batteries. Several key characteristics of lithium-ion ...
(Date:7/24/2014)...  CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical ... for the prevention and treatment of cardiorenal and ... July 18, 2014 from the NYSE MKT LLC ... plan to regain compliance with continued listing standards ... is continuing the Company,s listing and has granted ...
(Date:7/24/2014)... 2014 2014 Deep Research Report ... a professional and in-depth research report on Potassium ... basic information, including its definition, classification, application, ... research covers the international market analysis, including China’s ... covering macroeconomic environment & economic situation analysis, the ...
Breaking Biology Technology:Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2Getting More Life out of Lithium-ion Batteries 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4
... , , ROCKVILLE, Md., ... has announced that 263 regulatory professionals achieved Regulatory Affairs ... RAC credential is administered by RAPS and is the ... product sector. , , (Logo: ...
... BEIJING, Sept. 4 /PRNewswire-Asia/ -- ... provider of biopharmaceutical products in China, announced today that,the ... Republic,of China has issued the initial order to Sinovac ... to the initial order, Sinovac is,required to complete the ...
... September 4 Karolinska Development (publ),today announced that one ... clinical study of its candidate drug, tafoxiparin, a,new drug ... promising results of the Phase II trial bring the ... strategy. , Dilafor,s candidate drug, ...
Cached Biology Technology:263 Regulatory Professionals Achieve RAC Certification 2263 Regulatory Professionals Achieve RAC Certification 3Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 2Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 3Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial 2Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial 3
(Date:7/24/2014)... 2014) Scientists at The New York Stem ... closer to creating a viable cell replacement therapy ... , For the first time, NYSCF scientists ... skin samples of patients with primary progressive multiple ... to induce these stem cells into becoming oligodendrocytes, ...
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... Hopkins scientists seems to have discovered an almost-too-easy way to ... potent versions. Their finding, reported this week in Nature, could ... but also other body tissues. What the researchers ... neural stem cells the sort that might be used ...
... The giant panda is not at an evolutionary dead end ... new research involving scientists from Cardiff University. Previous ... requirements and slow reproductive rates have led to a lack ... extinction. Now a study by Professor Michael Bruford ...
... August 23, 2007 On August 16, the Food and ... sold under the brand name Coumadin. The new label suggests ... be safer for patients with variations in two genes, CYP2C9 ... testing, which may be a useful tool in determining appropriate ...
Cached Biology News:When is a stem cell not really a stem cell? 2American College of Medical Genetics responds to new FDA labeling decision for warfarin 2
Request Info...
supplied with 10x reaction buffer...
... from yeast/leuconostoc overproducer ATP: ... EC 2.7.1.1/1.1.1.49. One unit of ... of D-glucose in 1 min ... One unit of G6P-DH will ...
Request Info...
Biology Products: